Four Questions Every Oral-Health Brand Should Ask Before Going to Market

Over 25 years of commercial leadership in the dental and oral health industry, I have seen more go-to-market strategies fail than succeed. The reason was rarely the product itself. Most were clinically sound, thoughtfully designed, and built on strong scientific foundations. They failed because the commercial architecture around them was incomplete.

A rigorous go-to-market strategy in oral health is not a launch plan. It is a set of honest answers to four questions. If you cannot answer all four with specificity and evidence, you are not ready to go to market. You are ready to spend money.

Question 1: Who is my professional gatekeeper, and why would they recommend me?

In oral health, the professional gatekeeper, typically a dentist or hygienist, is the single most powerful commercial lever you have. Their recommendation converts at 70–80%. However, being recommended by these individuals is not an easy task, and it is not just about having a great product.

You need to answer: who are the particular clinicians who would be ready to recommend my product, and how can I help them do that easily? That means knowing their clinical issues, their time constraints, their communication preferences, and the kind of evidence needed for recommending a product.

Many brands believe that efficacy alone is sufficient to gain recommendations. Professionals need to understand your product’s clinical story in the context of their practice, have materials they can use chairside, and trust that your company is a credible long-term partner, not a product that will disappear in 18 months.

Question 2: What is my portfolio’s clinical story, and does it stand up to scrutiny?

The oral-health market is undergoing a fundamental shift. The fastest-growing segments, smart devices, therapeutic mouthwash, oral diagnostics are precisely where clinical positioning creates pricing power. Commodity oral care is growing below inflation in real terms. The brands winning margin are those that have moved from cosmetic to clinical positioning.

This means your portfolio needs a coherent clinical story. Not just a list of features, but a credible narrative about how your products contribute to health outcomes, particularly as the oral-systemic health evidence base matures. A major meta-analysis published in the Journal of General Internal Medicine found that severe periodontitis increases cardiovascular event risk by approximately 24–34%. Consumer search interest in “oral health and heart disease” has risen significantly year-on-year. The category is being redefined around health, and your clinical story needs to meet that moment.

Pressure-test your claims. Can your clinical story survive scrutiny from a periodontologist? Can a hygienist explain it in 60 seconds? Is it differentiated from what competitors are saying? If your story is “our toothbrush cleans teeth well,” you are competing on commodity terms.

Question 3: Where does my margin come from, commodity volume or clinical premium?

The global oral care market is projected to reach approximately $53 billion by 2030, but value is concentrated in clinical segments while commodity categories face margin erosion from private-label encroachment (22–28% of toothpaste volume in the UK, France, and Germany) and promotional dependency (up to 40% of UK/US mass market volume sold on deal).

Your go-to-market strategy must be honest about where margin comes from. If you are positioned as a commodity product, your growth strategy is volume-dependent and your margin is structurally under pressure. If you can position in the clinical or systemic tier, backed by evidence, earned through professional endorsement, you unlock premium pricing (+20–60% above core) and build a margin moat that commodity competitors cannot cross.

This is not an abstract question. It determines everything: your channel strategy, your pricing architecture, your field investment, and whether you can afford to build the professional advocacy system that will define your long-term competitiveness.

Question 4: What infrastructure do I need to scale beyond launch?

The most common failure mode in oral-health go-to-market is a strong launch that cannot scale. The founder’s energy, the initial PR, the early professional relationships, these carry the first 12 months. At that point, the infrastructure gap becomes visible: no CRM, no field force organisation, no way to measure recommendations, no process of professional interaction, no measurement tying marketing dollars to business impact.

Before going to market, plan the necessary infrastructure as if you’re 2x and 5x the size of your launch. Infrastructure needs usually include: A CRM system to measure professional and consumer interactions together; a scalable field force approach (even if you start with just three people); measurement of professional recommendation against consumer purchase; and a process or cadence of execution, weekly, monthly, quarterly.

Those who build the infrastructure before they need it will scale. The brands that try to retrofit it while growing will stumble.

A rigorous go-to-market strategy is not a launch plan. It is the honest answer to four questions. If you cannot answer all four, you are not ready to go to market. You are ready to spend money.

FAQ